Blueprint Medicines Co. (NASDAQ:BPMC) Insider Sells $324,499.56 in Stock

Blueprint Medicines Co. (NASDAQ:BPMC) insider Fouad Namouni sold 3,633 shares of the firm’s stock in a transaction on Thursday, October 3rd. The shares were sold at an average price of $89.32, for a total value of $324,499.56. Following the transaction, the insider now directly owns 69,070 shares in the company, valued at $6,169,332.40. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this link.

Blueprint Medicines Stock Performance

Blueprint Medicines stock opened at $88.61 on Monday. Blueprint Medicines Co. has a fifty-two week low of $43.89 and a fifty-two week high of $121.90. The firm’s 50 day simple moving average is $92.59 and its 200-day simple moving average is $99.04. The company has a debt-to-equity ratio of 1.06, a current ratio of 3.71 and a quick ratio of 3.65. The company has a market cap of $5.55 billion, a P/E ratio of -18.42 and a beta of 0.58.

Blueprint Medicines (NASDAQ:BPMC) last posted its quarterly earnings data on Thursday, August 1st. The biotechnology company reported ($0.80) earnings per share for the quarter, topping the consensus estimate of ($1.29) by $0.49. The firm had revenue of $138.20 million for the quarter, compared to analysts’ expectations of $104.02 million. Blueprint Medicines had a negative net margin of 56.64% and a negative return on equity of 157.30%. The company’s quarterly revenue was up 139.9% compared to the same quarter last year. During the same period in the previous year, the company posted ($2.19) EPS. As a group, equities research analysts predict that Blueprint Medicines Co. will post -3.99 EPS for the current year.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of BPMC. Amalgamated Bank grew its stake in Blueprint Medicines by 5.3% during the 2nd quarter. Amalgamated Bank now owns 2,154 shares of the biotechnology company’s stock valued at $232,000 after acquiring an additional 109 shares in the last quarter. Van ECK Associates Corp grew its position in Blueprint Medicines by 13.3% during the second quarter. Van ECK Associates Corp now owns 1,116 shares of the biotechnology company’s stock valued at $120,000 after purchasing an additional 131 shares in the last quarter. EFG Asset Management North America Corp. increased its stake in Blueprint Medicines by 0.5% in the 2nd quarter. EFG Asset Management North America Corp. now owns 27,884 shares of the biotechnology company’s stock valued at $3,008,000 after buying an additional 132 shares during the period. US Bancorp DE lifted its position in Blueprint Medicines by 5.2% in the 1st quarter. US Bancorp DE now owns 3,724 shares of the biotechnology company’s stock worth $353,000 after buying an additional 183 shares in the last quarter. Finally, Mackenzie Financial Corp boosted its stake in shares of Blueprint Medicines by 5.2% during the 2nd quarter. Mackenzie Financial Corp now owns 4,885 shares of the biotechnology company’s stock valued at $527,000 after buying an additional 243 shares during the period.

Analysts Set New Price Targets

Several research firms have commented on BPMC. Guggenheim raised their target price on shares of Blueprint Medicines from $130.00 to $138.00 and gave the company a “buy” rating in a research note on Friday, August 2nd. Oppenheimer raised their price objective on shares of Blueprint Medicines from $114.00 to $125.00 and gave the company an “outperform” rating in a research note on Monday, July 8th. Robert W. Baird upped their target price on Blueprint Medicines from $112.00 to $127.00 and gave the stock an “outperform” rating in a research report on Friday, August 2nd. Barclays increased their price target on Blueprint Medicines from $75.00 to $105.00 and gave the company an “equal weight” rating in a research note on Monday, July 29th. Finally, Baird R W raised Blueprint Medicines to a “strong-buy” rating in a research note on Friday, August 2nd. One equities research analyst has rated the stock with a sell rating, six have assigned a hold rating, eleven have issued a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat.com, Blueprint Medicines has a consensus rating of “Moderate Buy” and an average target price of $120.00.

About Blueprint Medicines

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders.